Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Launches Prasugrel In UK

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo launched April 8 antiplatelet agent Efient (prasugrel) in the UK. The launch is the first for prasugrel in the world. Daiichi obtained European approval in February. Jointly developed with Ube Industrials, Daiichi Sankyo is collaborating with Eli Lilly to develop and market the drug in the U.S. and Europe. The two plan to launch prasugrel to German and French markets shortly. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071295

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel